Á lódáil...
KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors
Imatinib and other BCR-ABL1 inhibitors are effective therapies for chronic myeloid leukemia (CML), but these inhibitors target additional kinases including KIT, raising the question of whether off-target effects contribute to clinical efficacy. Based on its involvement in CML pathogenesis, we hypoth...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
2013
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3894913/ https://ncbi.nlm.nih.gov/pubmed/23887971 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-1318 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|